Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy

Head Neck. 2008 Dec;30(12):1535-42. doi: 10.1002/hed.20902.

Abstract

Background: Determining which patients benefit from larynx preservation strategies remains problematic. We reviewed our experience using multiagent concurrent chemoradiotherapy to identify clinical predictors for success.

Methods: Cisplatin and fluorouracil were given during weeks 1 and 4 of radiation to 115 patients with locoregionally advanced larynx or hypopharynx squamous cell cancer without cartilage invasion or laryngeal destruction. Laryngectomy was reserved for local failure.

Results: The 5-year Kaplan-Meier projected overall survival was 58%, survival with larynx preservation 52%, local control without surgery 82%, local control (including surgical salvage) 94%, and survival with functional larynx 49%. Local control without surgery was superior in patients with T1-2 versus T3-4 tumors (97% vs 77%, p = .032). No other clinical parameters proved predictive of local control.

Conclusion: Larynx preservation was successful in all subsets of appropriately selected patients. Although local failure was more likely in patients with T3-4 tumors, it was infrequent and surgical salvage was effective.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Cisplatin / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Hypopharyngeal Neoplasms / drug therapy
  • Hypopharyngeal Neoplasms / radiotherapy
  • Kaplan-Meier Estimate
  • Laryngeal Neoplasms / drug therapy*
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / radiotherapy*
  • Laryngeal Neoplasms / surgery
  • Laryngectomy
  • Male
  • Middle Aged
  • Neoplasms, Squamous Cell / drug therapy*
  • Neoplasms, Squamous Cell / pathology
  • Neoplasms, Squamous Cell / radiotherapy*
  • Neoplasms, Squamous Cell / surgery
  • Patient Participation
  • Patient Selection
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome

Substances

  • Cisplatin
  • Fluorouracil